News Release

Two journal articles cite HemogloBind™ to remove analytical interferences from Hemoglobin

MONMOUTH JUNCTION, NJ, September 8, 2021 -- Biotech Support Group reports on two journal articles describing the simplicity and efficiency of their HemogloBind™ sample preparation technology for removing analytical interferences, in the measurements of total urine protein, and western blot respectively. The first citation is:

Juriasingani, Smriti, et al. "Evaluating the Effects of Subnormothermic Perfusion with AP39 in a Novel Blood-Free Model of Ex Vivo Kidney Preservation and Reperfusion." International Journal of Molecular Sciences 22.13 (2021): 7180.

This study evaluated whether adding hydrogen sulfide donor AP39 to Hemopure, a blood substitute, during subnormothermic perfusion improves kidney outcomes. Because of the added Hemopure, the article states, “Most of the urine samples collected were heavily pigmented, due to the presence of hemoglobin from the Hemopure, which prevented the use of conventional urinalysis methods. A 1:3 dilution of urine in Hemoglobind (Biotech Support Group, Monmouth Junction, NJ, USA) allowed us to obtain clearer urine samples after 10 min of vigorous shaking and centrifugation at 12,000× g.“ The investigation concluded that subnormothermic perfusion at 21 °C with Hemopure + 200 nM AP39 improves renal outcomes. 

The second citation is:

D'Alessandro, Angelo, et al. "Hematologic and systemic metabolic alterations due to Mediterranean type II G6PD deficiency in a novel murine model." bioRxiv (2021).

Deficiency of Glucose 6 phosphate dehydrogenase (G6PD) is the single most common enzymopathy, present in approximately 400 million humans (e.g. 5% of humans). G6PD deficiency is associated with kidney disease, diabetes, pulmonary hypertension, immunological defects, and neurodegenerative diseases. To generate a more accurate model of deficiency, the human sequence for a severe form of G6PD deficiency (Med -) was knocked into the murine G6PD locus and confirmed by Western blot. The article states “Briefly, RBCs were washed 3 times PBS, followed by transfer of one part washed RBCs into three parts water, followed by end over end rotation for 5 min at room temperature to lyse the RBCs. Lysed RBCs were then mixed 1:1 with HemogloBind (Biotech Support Group), followed by end over end rotation for 10 min at room temperature. HemogloBind and bound hemoglobin were pelleted by centrifugation, and supernatants subjected to an additional hemoglobin depletion with HemogloBind. Supernatants were used for western blotting.” The authors’ findings both establish a new mouse model of G6PD deficiency that more accurately reflects human G6PD deficiency, and also advance our basic understanding of altered metabolism in this setting. 

“The large amount of hemoglobin in many samples presents a special challenge for quantitative analysis. These two articles illustrate the versatility of HemogloBind™ to reduce the interference associated with large concentrations of hemoglobin, without compromising the recovery and analysis of the protein(s) of interest.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HmoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on personalized medical decisions for cancer and Covid-19 patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com